[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577171":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":32,"collaborators":35,"id":45,"slug":7,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":7,"enrollmentInfo":54,"targetDuration":7,"studyType":57,"phases":7,"briefSummary":58,"conditions":59,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Leiden University Medical Center","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Y.K. Onno Teng","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Y.K.O. Teng, MD, PhD","CONTACT","+31715262148","y.k.o.teng@Lumc.nl",[19],{"facility":5,"status":20,"city":21,"state":7,"zip":7,"country":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"RECRUITING","Leiden","Netherlands",{"type":24,"coordinates":25},"Point",[26,27],4.49306,52.15833,{"lat":27,"lon":26},[30],{"name":31,"role":15,"phone":7,"phoneExt":7,"email":17},"YKO Teng, MD, PhD",{"type":11,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Y.K.Onno Teng","Clinical Professor",[36,38,40,42],{"name":37,"class":6},"University of Udine",{"name":39,"class":6},"University of Modena and Reggio Emilia",{"name":41,"class":6},"Hospital Universitari de Bellvitge",{"name":43,"class":44},"ZOL Hospital Genk Belgium","UNKNOWN","100577171",false,"NCT06794827","Early-access Avacopan in Real-world ANCA-associated Vasculitis","Evaluating Clinical Practice of Early Access Avacopan Treatment for ANCA-associated Vasculitis in European Countries","AVAC-EUR","Inclusion Criteria:\n\n* Established diagnosis of GPA or MPA\n* Treatment (initiation) with avacopan\n* Informed consent for use of medical data\n\nExclusion Criteria:\n\n* If there is no AAV disease activity present that can be supported by an objectifiable clinical measure or assessment\n* If a subject is below 16 years old","ALL","16 Years",{"count":55,"type":56},100,"ESTIMATED","OBSERVATIONAL","The current study proposal aims to investigate the clinical practice variation of the initial use of avacopan for AAV patients in Europe. The study will describe patient characteristics and organ-specific clinical benefit of avacopan treatment in a unique, first-experience cohort of AAV patients. By studying the clinical practice variation of first-experience avacopan treatment, this study will be uniquely positioned to identify pivotal issues on the real-life implementation of avacopan treatment. These observational data can ultimately serve to address current knowledge gaps on avacopan treatment in AAV patients, improve the care and drug-access for AAV patients with avacopan treatment and generate new areas of research.",[60],"ANCA Associated Vasculitis","2025-01-22",{"date":63,"type":64},"2025-01-27","ACTUAL",{"date":66,"type":64},"2023-11-01",{"date":68,"type":56},"2026-12-31",{"name":5,"class":6},1]